Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Sushanth Gouni"'
Autor:
Paolo Strati, Lei Feng, Jason Westin, Ranjit Nair, Sushanth Gouni, Luis Fayad, Maria Rodriguez, Dai Chihara, Luis Malpica, Raphael Steiner, Mariana Gallardo, Loretta J. Nastoupil, Sattva Neelapu
Publikováno v:
HemaSphere, Vol 7, p e6330214 (2023)
Externí odkaz:
https://doaj.org/article/07f72bc945224503956178db4ca6b20e
Autor:
Andrew P. Jallouk, Sushanth Gouni, Jason Westin, Lei Feng, Haleigh Mistry, Raphael E. Steiner, Jinsu James, Mansoor Noorani, Sandra Horowitz, Nahum Puebla-Osorio, Luis E. Fayad, Swaminathan P. Iyer, Misha Hawkins, Christopher R. Flowers, Sairah Ahmed, Loretta J. Nastoupil, Partow Kebriaei, Elizabeth J. Shpall, Sattva S. Neelapu, Yago Nieto, Paolo Strati
Publikováno v:
Haematologica, Vol 108, Iss 4 (2022)
Externí odkaz:
https://doaj.org/article/e594de9ca2264723b1d6eb36952f069d
Autor:
Mario L. Marques-Piubelli, Luisa M. Solis, Edwin R. Parra, Luis Malpica Castillo, Sushanth Gouni, Ranjit Nair, Dai Chihara, Marina Konopleva, Ignacio I. Wistuba, Swaminathan P. Iyer, Francisco Vega, Paolo Strati
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 9, Pp 1-4 (2021)
Externí odkaz:
https://doaj.org/article/6130830d682f4eefbb3bb5566d89c087
Autor:
Katia Bravo-Jaimes, Nicolas L. Palaskas, Jose Banchs, Nadia I. Abelhad, Alveena Altaf, Sushanth Gouni, Juhee Song, Saamir A. Hassan, Cezar Iliescu, Anita Deswal, Syed Wamique Yusuf
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 8 (2021)
Patients with cancer and aortic stenosis (AS) are exposed to several factors that could accelerate the progression of AS. This study aimed to determine the cumulative incidence of AS progression and associated factors in these patients. This retrospe
Externí odkaz:
https://doaj.org/article/468742d19e69476f9df7d61478113343
Autor:
Sushanth Gouni, Paolo Strati, Gokce Toruner, Akanksha Aradhya, Ralf Landgraf, Daniel Bilbao, Francisco Vega, Nitin Kumar Agarwal
Publikováno v:
Leukemia & Lymphoma. 63:1302-1313
The beneficial effect of statins on the anti-lymphoma activity of the rituximab-based chemotherapy regimen is controversial. Here, we retrospectively reviewed patients with naïve-treated advanced diffuse large B-cell lymphoma (DLBCL) receiving front
Autor:
Mario L. Marques-Piubelli, Edwin R. Parra, Lei Feng, Luisa Solis Soto, Mariana Gallardo, Sushanth Gouni, Felipe Samaniego, Mansoor Noorani, Fredrick B. Hagemeister, Jason R. Westin, Hun Ju Lee, Maria A. Rodriguez, Sattva S. Neelapu, Jillian R. Gunther, Nathan H. Fowler, Christopher R. Flowers, Ignacio I. Wistuba, Loretta J. Nastoupil, Francisco Vega, Paolo Strati
Publikováno v:
Blood advances. 6(11)
Limited data exist regarding the outcome of patients with follicular lymphoma (FL) who relapse or progress after frontline lenalidomide and rituximab (R2). Moreover, mechanisms of resistance to R2 in FL remain unclear, with increased protumoral macro
Autor:
Sushanth Gouni, Allison C. Rosenthal, Jennifer L. Crombie, Andrew Ip, Manali K. Kamdar, Brian Hess, Lei Feng, Grace Watson, Amy Ayers, Sattva S. Neelapu, Arushi Khurana, Yi Lin, Madiha Iqbal, Reid W. Merryman, Paolo Strati
Publikováno v:
Blood advances. 6(9)
Polatuzumab vedotin (PV) is an antibody–drug conjugate targeting CD79b that is approved for patients with relapsed/refractory large B-cell lymphoma (LBCL). Patients who relapse after chimeric antigen receptor (CAR) T-cell therapy were not included
Autor:
Marina Konopleva, Dai Chihara, Edwin R. Parra, Mario L. Marques-Piubelli, Swaminathan P. Iyer, Paolo Strati, Francisco Vega, Luis Malpica Castillo, Ranjit Nair, Luisa M. Solis, Ignacio I. Wistuba, Sushanth Gouni
Publikováno v:
Blood Cancer Journal
Blood Cancer Journal, Vol 11, Iss 9, Pp 1-4 (2021)
Blood Cancer Journal, Vol 11, Iss 9, Pp 1-4 (2021)
Autor:
Paolo Strati, Allison Rosenthal, Sushanth Gouni, Jennifer Crombie, Andrew Ip, Manali Kamdar, Brian Hess, Lei Feng, Grace Watson, Amy Ayers, Arushi Khurana, Madiha Iqbal, Yi Lin, Reid Merryman, Sattva S. Neelapu
Publikováno v:
Transplantation and Cellular Therapy. 28:S405-S406
Publikováno v:
Blood advances. 5(20)
The survival and proliferation of follicular lymphoma (FL) cells are strongly dependent on macrophages, because their presence is necessary for the propagation of FL cells in vitro. To this regard, as also shown for the majority of solid tumors, a hi